https://the483.com/akeso-ivonescimab-harmoni6-squamous-nsclc/ The 483 en 2026-05-31T22:35:34.000Z Akeso Ivonescimab Cuts Death Risk 34% in Squamous NSCLC https://the483.com/omb-files-grant-rule-cancel-anytime/ The 483 en 2026-05-31T22:06:41.000Z OMB Files Grant Rule: Agencies Cancel at Any Time https://the483.com/erleada-proteus-prostate-surgery-metastasis/ The 483 en 2026-05-31T21:35:43.000Z Cuts Metastasis Risk 20%: J&J's Erleada Targets Surgery https://the483.com/ivonescimab-harmoni6-squamous-nsclc-os/ The 483 en 2026-05-31T21:07:08.000Z Ivonescimab Cuts NSCLC Death Risk 34% in Phase 3 https://the483.com/lilly-kelonia-car-t-myeloma/ The 483 en 2026-05-31T20:44:24.473Z Lilly Paid $3.2B for Kelonia's 100% CAR-T Response https://the483.com/oppfi-beats-dfpi-true-lender/ The 483 en 2026-05-31T09:19:37.000Z Rejected: DFPI's True Lender Claim Against OppFi https://the483.com/gilead-tubulis-tub040-ovarian-adc/ The 483 en 2026-05-31T09:17:51.472Z Gilead Paid $3.15B for Tubulis; TUB-040 Posts 61% ORR https://the483.com/kalshi-cftc-sue-minnesota-prediction-ban/ The 483 en 2026-05-30T22:34:19.000Z Kalshi, CFTC Sue Minnesota Over Felony Prediction Ban https://the483.com/pets-cross-border-data-pilot/ The 483 en 2026-05-30T22:06:43.000Z PETs Cut Cross-Border Approvals From 12 Months to 2 https://the483.com/incyte-monjuvi-dlbcl-phase3/ The 483 en 2026-05-30T21:35:43.000Z Cuts DLBCL Risk 25%: Monjuvi Takes On Polivy https://the483.com/pfizer-talzenna-52pct-mcspc-pfs/ The 483 en 2026-05-30T21:06:57.000Z Pfizer Cuts J&J's mCSPC Lead With 52% PFS Win https://the483.com/summit-ivonescimab-harmoni6-asco-plenary/ The 483 en 2026-05-29T23:09:29.000Z Summit's Ivonescimab OS Data Could Shake NSCLC Billions